JP2015522576A5 - - Google Patents

Download PDF

Info

Publication number
JP2015522576A5
JP2015522576A5 JP2015519089A JP2015519089A JP2015522576A5 JP 2015522576 A5 JP2015522576 A5 JP 2015522576A5 JP 2015519089 A JP2015519089 A JP 2015519089A JP 2015519089 A JP2015519089 A JP 2015519089A JP 2015522576 A5 JP2015522576 A5 JP 2015522576A5
Authority
JP
Japan
Prior art keywords
amino acid
ankyrin repeat
optionally replaced
binding protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015519089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015522576A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/063488 external-priority patent/WO2014001442A1/en
Publication of JP2015522576A publication Critical patent/JP2015522576A/ja
Publication of JP2015522576A5 publication Critical patent/JP2015522576A5/ja
Pending legal-status Critical Current

Links

JP2015519089A 2012-06-28 2013-06-27 血小板由来成長因子に結合する設計アンキリンリピートタンパク質 Pending JP2015522576A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12174020.3 2012-06-28
EP12174020 2012-06-28
PCT/EP2013/063488 WO2014001442A1 (en) 2012-06-28 2013-06-27 Designed ankyrin repeat proteins binding to platelet-derived growth factor

Publications (2)

Publication Number Publication Date
JP2015522576A JP2015522576A (ja) 2015-08-06
JP2015522576A5 true JP2015522576A5 (enExample) 2016-09-23

Family

ID=48699826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015519089A Pending JP2015522576A (ja) 2012-06-28 2013-06-27 血小板由来成長因子に結合する設計アンキリンリピートタンパク質

Country Status (16)

Country Link
US (2) US9163070B2 (enExample)
EP (1) EP2867360B1 (enExample)
JP (1) JP2015522576A (enExample)
KR (1) KR20150023957A (enExample)
CN (1) CN104508129A (enExample)
AU (1) AU2013283296A1 (enExample)
BR (1) BR112014032316A2 (enExample)
CA (1) CA2877584A1 (enExample)
HK (1) HK1209156A1 (enExample)
IL (1) IL236428A0 (enExample)
IN (1) IN2014MN02522A (enExample)
MX (1) MX2014015825A (enExample)
RU (1) RU2014150224A (enExample)
SG (1) SG11201408196RA (enExample)
WO (1) WO2014001442A1 (enExample)
ZA (1) ZA201408872B (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
EP2643349B1 (en) 2010-11-26 2019-09-04 Molecular Partners AG Designed repeat proteins binding to serum albumin
WO2013169614A1 (en) 2012-05-07 2013-11-14 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
US10665324B2 (en) 2014-07-07 2020-05-26 Yeda Research And Development Co. Ltd. Method of computational protein design
WO2016023898A2 (en) * 2014-08-11 2016-02-18 Medimmune Limited Intracellular antigen binding
BR112017009792A2 (pt) 2014-11-10 2018-02-27 Hoffmann La Roche anticorpos anti-pdgf-b e métodos de uso
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 二重特異性抗体及び眼科に使用する方法
AU2015345320A1 (en) 2014-11-10 2017-04-06 F. Hoffmann-La Roche Ag Anti-IL-1beta antibodies and methods of use
BR112017009790A2 (pt) 2014-11-10 2017-12-19 Hoffmann La Roche anticorpos direcionados ao anti-ang2 e métodos de uso
US9458211B1 (en) 2015-04-02 2016-10-04 Molecular Partners Ag Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains
US10283384B2 (en) * 2015-04-27 2019-05-07 Taiwan Semiconductor Manufacturing Co., Ltd. Method for etching etch layer and wafer etching apparatus
AR109680A1 (es) 2016-09-22 2019-01-09 Molecular Partners Ag Proteínas recombinantes y sus usos
US10037890B2 (en) * 2016-10-11 2018-07-31 Lam Research Corporation Method for selectively etching with reduced aspect ratio dependence
WO2018165046A1 (en) 2017-03-07 2018-09-13 Igc Bio, Inc. A computational pipeline for antibody modeling and design
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
WO2019180243A1 (en) 2018-03-22 2019-09-26 Charité-Universitätsmedizin Berlin Crispr associated protein reactive t cell immunity
WO2019238966A1 (en) 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
MX2021004012A (es) 2018-10-08 2021-06-23 Univ Zuerich Polipeptidos tetramericos de union a her2.
US20220017433A1 (en) 2018-11-21 2022-01-20 Universität Zürich Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
EP3677911A3 (en) 2019-01-03 2020-07-29 Universität Basel Use of non-agonist ligands for suppression of metastasis
WO2020144378A1 (en) 2019-01-11 2020-07-16 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
EP3953712A1 (en) 2019-04-10 2022-02-16 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
AU2020286600A1 (en) * 2019-06-04 2021-12-23 Molecular Partners Ag Recombinant FAP binding proteins and their use
AU2020289080A1 (en) 2019-06-04 2021-12-23 Molecular Partners Ag Multispecific proteins
EP3980452A1 (en) * 2019-06-04 2022-04-13 Molecular Partners AG Recombinant 4-1bb binding proteins and their use
WO2021044050A1 (en) 2019-09-05 2021-03-11 Genome Biologics Ug Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure
CN114929730A (zh) 2019-12-11 2022-08-19 分子合作伙伴股份公司 重组肽-mhc复合物结合蛋白及其生成和用途
WO2021122813A1 (en) 2019-12-16 2021-06-24 Universität Basel Angiogenesis promoting agents for prevention of metastatic cancer
WO2021176008A1 (en) 2020-03-04 2021-09-10 Cornell University Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
US20230151118A1 (en) 2020-04-06 2023-05-18 Universität Zürich Artc1 ligands for cancer treatment
MX2022013945A (es) 2020-05-06 2023-02-14 Molecular Partners Ag Nuevas proteinas de union a repeticiones de anquirina y sus usos.
JP2023528204A (ja) 2020-05-14 2023-07-04 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
WO2021239844A1 (en) 2020-05-27 2021-12-02 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes
WO2021239999A1 (en) 2020-05-28 2021-12-02 Universität Zürich Il-12 pd-l1 ligand fusion protein
KR20230048151A (ko) 2020-08-18 2023-04-10 유니버시타트 취리히 Cd25 편향된 항-il-2 항체
WO2022130300A1 (en) 2020-12-16 2022-06-23 Molecular Partners Ag Novel slow-release prodrugs
EP4291901B1 (en) 2021-02-11 2025-05-07 Universität Zürich Use of markers found on lymph node metastatic samples for the prognosis of breast cancer
JP2024509904A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規なDARPinに基づく多重特異性T細胞エンゲージャ
US20240156980A1 (en) 2021-03-09 2024-05-16 Molecular Partners Ag Protease cleavable prodrugs
EP4304730A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Novel darpin based cd33 engagers
AU2022233791A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd123 engagers
AU2022322029A1 (en) 2021-08-05 2024-02-15 Immunos Therapeutics Ag Combination medicaments comprising hla fusion proteins
ES3048791T3 (en) 2021-08-05 2025-12-11 Immunos Therapeutics Ag Pharmaceutical compositions comprising hla fusion proteins
WO2023021006A1 (en) 2021-08-16 2023-02-23 Universität Zürich Il-1 targeting agents for treatment of pitiyriasis rubra pilaris
WO2023036849A1 (en) 2021-09-07 2023-03-16 ETH Zürich Identifying and predicting future coronavirus variants
EP4163380A1 (en) 2021-10-08 2023-04-12 ETH Zurich Device and method for manipulation of extracellular vesicles
IL313411A (en) 2021-12-14 2024-08-01 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
EP4260907A1 (en) 2022-04-11 2023-10-18 Universität Zürich Agents for treatment of endometriosis and other benign gynecological neoplasms
WO2024002914A1 (en) 2022-06-27 2024-01-04 Charité-Universitätsmedizin Berlin Prediction of, and composition to improve, tendon healing
CN119731200A (zh) 2022-08-01 2025-03-28 分子合作伙伴股份公司 经电荷修饰设计的重复结构域及其用途
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
JP2026500369A (ja) 2022-12-19 2026-01-06 マックス-プランク-ゲゼルシャフト ツール フェルデルンク デル ヴィッセンシャフテン エー.ファウ. 内因性凝縮体を標的とする手段及び方法
EP4662230A1 (en) 2023-02-08 2025-12-17 ImmunOs Therapeutics AG Fusion proteins of ss2 microglobulin, hla heavy chain polypeptides, and inhibitor of cd47-sirpa
WO2024179981A1 (en) 2023-02-27 2024-09-06 Molecular Partners Ag Darpins for use in reducing renal accumulation of drugs
WO2025008519A1 (en) 2023-07-05 2025-01-09 Universität Bern Il-1ra blockers for treatment and prevention of sepsis
WO2025021293A1 (en) 2023-07-25 2025-01-30 Universität Zürich Disruption of rbr1 expression in plant cells
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025202503A1 (en) 2024-03-28 2025-10-02 Universität Zürich Extracellular vesicles carrying cancer specific splice variants

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5094941A (en) * 1987-12-31 1992-03-10 Zymogenetics, Inc. Monoclonal antibodies to PDGF
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
WO1998048008A1 (en) 1997-04-23 1998-10-29 Plueckthun Andreas Methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules
ATE354675T1 (de) 1998-12-02 2007-03-15 Adnexus Therapeutics Inc Dna-protein fusionen sowie anwendungen derselben
CA2421447C (en) * 2000-09-08 2012-05-08 Universitat Zurich Collections of repeat proteins comprising repeat modules
EP1436329A4 (en) * 2001-09-20 2005-04-27 Alexion Pharma Inc ANTI-PDGF ANTIBODIES AND METHODS FOR PRODUCING FOCUSED ANTIBODIES
AU2004268614C1 (en) * 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
CN101875919A (zh) * 2004-11-12 2010-11-03 拜耳先灵医药股份有限公司 重组新城疫病毒
US7875465B2 (en) * 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
RU2412249C2 (ru) 2005-07-08 2011-02-20 Юниверсити Оф Цюрих Фаговый дисплей с применением котрансляционной транслокации слитых полипептидов
EP2863222A1 (en) 2006-03-06 2015-04-22 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
HRP20110368T1 (hr) 2007-06-21 2011-06-30 Technische Universitt Mnchen Biološki aktivni proteini s povećanom stabilnošću in vivo i/ili in vitro
EP2641919A3 (en) 2007-11-30 2014-05-07 Glaxo Group Limited Antigen-binding constructs
US20100317599A1 (en) * 2008-02-13 2010-12-16 Alrik Pieter Los Process for the production of a peptide
EP2263088A2 (en) * 2008-03-19 2010-12-22 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
EP2358746B1 (en) * 2008-11-03 2020-09-16 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
TW201120210A (en) * 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
EP2643349B1 (en) * 2010-11-26 2019-09-04 Molecular Partners AG Designed repeat proteins binding to serum albumin
KR20140039203A (ko) * 2011-04-29 2014-04-01 얀센 바이오테크 인코포레이티드 Il4/il13 결합 반복 단백질 및 용도

Similar Documents

Publication Publication Date Title
JP2015522576A5 (enExample)
RU2014150224A (ru) Сконструированный белок с анкириновым повтором, связывающийся с фактором роста тромбоцитов
RU2017134456A (ru) Рекомбинантные связывающие белки и их применение
JP2018511327A5 (enExample)
JP2012507271A5 (enExample)
JP2010516290A5 (enExample)
JP2010519931A5 (enExample)
RU2011122201A (ru) Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
JP2015502346A5 (enExample)
NZ602943A (en) Modified binding proteins inhibiting the vegf-a receptor interaction
JP2012115277A5 (enExample)
JP2016512213A5 (enExample)
JP2019531093A5 (enExample)
JP2017006120A5 (enExample)
JP2010166916A5 (enExample)
RU2015120663A (ru) Связывающие белки, содержащие, по меньшей мере, две повторяющиеся области-антагонисты HER2
JP2015537044A5 (enExample)
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
JP2017537926A5 (enExample)
JP2019510739A5 (enExample)
JP2017506521A5 (enExample)
JP2020503262A5 (ja) アクチビンIIa型受容体変異体および同変異体を含む医薬組成物
JP2014510519A5 (enExample)
JPWO2019156137A5 (enExample)
JP2006506942A5 (enExample)